UnitedHealth Pulls 2025 Outlook and Replaces CEO

Morningstar’s Metrics for UnitedHealth Group

• Fair Value Estimate: $530.00
• Morningstar Rating: ★★★★
• Morningstar Economic Moat Rating: Narrow
• Morningstar Uncertainty Rating: High

UnitedHealth Group UNH shares fell nearly 10% in early trading on May 13 after the company pulled its 2025 guidance on surging medical utilization and replaced CEO Andrew Witty with its current chairman and former CEO from 2006-17, Stephen Hemsley.

Why it matters: Challenges continue to pile up for UnitedHealth, which has caused shares to drop from over $600 on the day of its key insurance executive’s killing in early December to below $350 per share in pre-market trading May 13.

• Since December, UnitedHealth shares have re-rated on broad regulatory concerns and company-specific questions around its coverage decisions, risk ratings in Medicare Advantage, conflicts between its medical insurance and Optum operations, and surging medical utilization.
• Although we suspect investors may eventually appreciate Hemsley taking a firmer grip on UnitedHealth while the major inputs for 2026’s results can still be influenced, the murky outlook for 2025 and executive suite shakeup inject more uncertainty into the situation.

The bottom line: While we are keeping our fair value estimate at $530 per share for now, we are raising our Uncertainty Rating to High from Medium to reflect the company-specific challenges that UnitedHealth faces, especially in the near term.

• Our narrow moat rating on UnitedHealth has not changed, and UnitedHealth remains the strongest managed care organization we cover, with a significant margin for executional error.
• Although we are keeping our Capital Allocation Rating at Exemplary, we may reconsider if Hemsley’s team cannot turn around the company’s execution in its risk-related businesses in 2026 and beyond.

Bulls say: While the 2025 outlook suspension is disappointing, management continued to highlight that it aims to eventually return to its earnings growth target of 13%-16%. Returning to that growth trajectory in the long run would make current share prices look very attractive.